CORCEPT THERAPEUTICS INC (CORT) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago ⓘ · Not investment advice

CORCEPT THERAPEUTICS INC

CORT Healthcare Pharmaceuticals📄 SEC filings ↗ CUSIP 218352102
Valuation N/A
Long-term trend (200d) 90% above 200-day Risk 53/100 Elevated
▾ What's in the 53/100 risk score? (higher = riskier)
Fundamental health (43%) 46/100 → +19.7
leverage 20/100 · FCF trend 80/100 · Altman Z not scored — input unavailable (see Financial Health)
Smart money (short interest + insider buying) (31%) 79/100 → +24.8
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 33/100 → +8.5
Total53/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). It excludes the Altman Z score, whose retained-earnings input this filer does not report separately. See the Financial Health section for the full balance-sheet read.

💵 Price $112.79 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago
📍 START HERE

How to read CORT

We are not publishing an intrinsic value for this one — the section below says exactly why. Everything on this page that comes straight from the filings and the tape is still here; treat the missing valuation as a known gap, not as a verdict on the business.

Where to start — the sections that matter most for this stock
  1. 1 Reported earnings & margins ↓
    What the company actually reported — unaffected by the valuation being held.
  2. 2 Balance sheet & book value ↓
    Assets, liabilities and equity as filed.
  3. 3 Who's selling & betting against it ↓
    Insider and short-interest behaviour needs no valuation model.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ No DCF yet — the company isn't generating positive free cash flow

A discounted-cash-flow model can only discount POSITIVE cash flows. CORT's free cash flow is currently negative — it's reinvesting / still pre-profit — so a forward DCF can't produce a meaningful number. That's a property of the model, not missing data; the full financials and story are below.

What to use instead: This is exactly where the Reverse-DCF earns its keep: it shows the growth the market is ALREADY pricing in, so you can judge whether that's achievable. Pair it with the EV/Sales peer lens, the Rule-of-40 read, and the cash-runway section — the right tools for a pre-profit company.

This note is only about the single DCF fair-value number — CORT's full financial statements, health scores, and written analysis are all below.

ⓘ Why does CORT trade at $112.79?

CORCEPT THERAPEUTICS INC has 120.0 million shares outstanding. At $112.79 per share, the market values all outstanding CORT equity at $13.5 billion. That's market capitalization, not enterprise value — enterprise value also accounts for debt and cash (CORT carries little or no debt, so the two are close here). The share price by itself tells you almost nothing — a company can pick any share price by splitting or issuing more shares. What matters is the total value (Market Cap?Market Cap — The total dollar value the market is assigning to the entire company.
Why it matters: This is the number that actually matters when comparing companies. Two companies with the same business but different share counts have the same market cap.
Reference: Mega cap >$200B · Large $10–200B · Mid $2–10B · Small $300M–2B · Micro <$300M
Full explanation →) compared to what the business actually produces. This page values CORT in Per Share?Per Share — A company-level figure divided by total shares — what one share represents.
Why it matters: Per-share metrics are the only way to fairly compare two companies with different share counts.
Full explanation → economics — what each share represents of the underlying business. Play with the share-price calculator on the homepage →

Loading insider & short-seller data…
Checking filings for failure warnings…
VALUATION RANGE — CROSS-METHOD CHECK

Football field: where does the price sit?

Different valuation methods produce different fair-value ranges depending on assumptions. Plotting them together lets you see at a glance whether the current price is reasonable across approaches, or only one specific lens.

$16$42$68$94$120Current price $112.79EV / Sales (p25→p75)$16.87$64.46
The current price sits ABOVE the high end of every method. The market is paying a premium to all of these lenses — it expects materially better growth or margins than the models assume.

Industry multiples sourced from: industry: Pharmaceuticals. See the Peer Basket section below for the peer comparison and its limited-comparables caveat.

PEER BASKET — TIGHT COMPARABLES

How does CORT stack up against its closest peers?

We take the 8 same-industry companies most similar to CORT (similar size) and check what investors are paying for each dollar of their revenue (or profits). If CORT is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.

▾ What's "EV / Sales" in plain English?

EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.

EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).

p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.

What peers trade at (p25 / median / p75)
EV / Sales?EV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt).
Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices.
Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding
Full explanation →		 7.4x / 8.9x / 9.8x

Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.

Peer-implied value check
$57.74
If CORT traded at the typical (median) peer's EV/Sales multiple, the share price would be about $57.74.
Plain English: the stock currently trades at $112.79. That's 95.3% MORE than the peer multiple suggests. The market is paying a big premium — CORT looks expensive vs peers. Either the market thinks this stock deserves a premium (faster growth, better margins, brand moat), or it's overpriced.

⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.

▾ View peer list (8)
Ticker Company Industry Mcap EV/Sales EV/GPEV/EBIT FCF Yield
SPRO Spero Therapeutics, Inc. Pharmaceuticals $12.4B 981.8x —1,957.0x 0.1%
RGC Regencell Bioscience Holdings Ltd Pharmaceuticals $11.8B — —— —
ZLAB Zai Lab Ltd Pharmaceuticals $19.6B 43.0x —— 0.8%
UTHR UNITED THERAPEUTICS Corp Pharmaceuticals $23.6B 7.4x 8.4x15.8x 3.3%
TGTX TG THERAPEUTICS, INC. Pharmaceuticals $5.8B 9.8x —49.1x 10.6%
XENE Xenon Pharmaceuticals Inc. Pharmaceuticals $5.3B 705.4x —— 0.0%
ATHE ALTERITY THERAPEUTICS LTD Pharmaceuticals $37.6B — —— —
TVTX Travere Therapeutics, Inc. Pharmaceuticals $4.4B 8.9x —— 4.6%
FINANCIAL HEALTH SCREENS

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
n/a
Not reliably computable

We can't produce a trustworthy Altman Z here: retained earnings weren't separately reported in our data, so a core input would have to be fabricated. Rather than show a categorical "distress" verdict from an invented number, we mark it unavailable. Judge financial health from the leverage, cash position, and the measurable Piotroski checks instead.

Piotroski-style checks (partial — not a standard F-score)
5 passed · 3 failed · 1 n/a
Partial result, not a standard F-score: 5 of 8 measurable checks passed. 1 of the 9 standard checks couldn't be measured, so this is scored out of 8, not 9 — it isn't comparable to a published F-score.
▾ The checks — what passed, what didn't (and what we couldn't measure)
  • ✓ Positive net income
    Net income $99.7M in FY2025.
  • ✓ Positive operating cash flow
    Operating cash flow $142.0M (was $198.3M the prior year).
  • ✓ Cash flow backs up reported profit
    Operating cash flow $142.0M vs net income $99.7M.
  • ✗ Return on assets improving
    Return on assets 11.9% vs 16.8% a year ago.
    Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
  • ✓ Debt load (vs assets)
    The filing reports no interest-bearing debt in either year (total assets $836.7M).
  • ✗ Short-term liquidity (current ratio)
    Current ratio 2.92x vs 3.35x a year ago.
    Why this matters: The current ratio compares assets it can turn to cash within a year against bills due within a year. Below 1.0 means it may struggle to cover near-term obligations.
  • ✗ Share count (dilution)
    Share count rose 5.7% (113.5M → 120.0M year-over-year).
    Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
  • · Pricing power (gross margin) (n/a — data not reported; not scored)
  • ✓ Sales per asset (asset turnover)
    Asset turnover 0.91x vs 0.80x a year ago.

Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.

INTERACTIVE — TWEAK YOUR ASSUMPTIONS

What if you assume different inputs?

Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount Rate?Discount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 10.0%, the figure our model used for CORT. Open Advanced to also change beta, growth and the rate path.

Note: no headline intrinsic value is published for this stock (the valuation is held for a data-quality reason — see the notes above). The calculator below is a what-if tool: the values it produces are your assumptions played out, not our estimate.

4.5% (risk-free)9-10% normal18% (deep-risk)
0%2-3% (GDP)5% (rarely sustainable)

A full intrinsic value isn't shown for CORT because the valuation is currently held for a data-quality reason (see the guardrail notes above). The reverse-DCF reading still works — it needs only the price and cash flow — but we won't publish a forward value until the underlying data passes our checks.

For comparison — the revenue growth today's price already assumes
—
—

—

⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Where the discount rate comes from — discount rate = risk-free + beta × equity-risk-premium
What you'd earn risk-free from government bonds — the floor under every other rate. Slide it down to model the market expecting rate cuts (value rises); up for higher-for-longer.
The extra yearly return investors demand for owning stocks instead of safe bonds — the price of risk. History runs ~4.5–6.5%; we default to 5.5% (slightly conservative). It's an estimate, not a law — lower it if you think equities are less risky than that.
Inflation reduces the purchasing power of a nominal return: a 9% gain at 3% inflation is about 6% in real terms. The intrinsic value above is already in today's dollars (a nominal DCF carries inflation in both the growth and the discount rate), so this switch does not change the value — it restates the return in real terms.
Higher beta → higher discount rate (sets the rate above). 1.0 = moves with the market.
What you think CORT can grow revenue for ~5 years, then fades to terminal.
For a pre-profit company: the % of revenue that eventually becomes free cash flow once mature. (Our published value uses the sector norm.)
All inputs start at the values our model used.

    Copy shareable link to this scenario →

    Price$112.79
    Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

    Corcept Therapeutics Inc. The market appears to be paying up for its consistent revenue growth of 20.1%/yr and its strong profitability, evidenced by positive net income and operating cash flow for the latest period and the past five years. The primary quantifiable risk is the model's low franchise/durability score of 2/5, suggesting potential long-term competitive challenges not reflected in the current premium. The market may be assigning value to future drug pipeline catalysts, which is not in the model.

    ⚠️ Operating CF declining

    As of 3 months ago

    ANATOMY

    Anatomy of a share

    What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

    CORT CORCEPT THERAPEUTICS INC stock anatomy showing per-share revenue, operating expenses, free cash flow, and debt
    13.1%
    profit
    Where each $1 of revenue goes
    Net profit — 13.1¢ of every dollar ($0.83/sh = latest fiscal-year net income ÷ current shares. The table below shows GAAP diluted EPS of $0.82, computed on that year's weighted-average diluted shares — the share count moved, which is why they differ)
    Costs & taxes — 86.9¢ (on $6.35 revenue/sh)
    Net margin = net income ÷ revenue (most recent fiscal year).
    Plain English: each share (at $113) represents $6.35 of revenue per share per year, $0.83 of net income per current share, and $0.48 of free cash flow per share from the latest fiscal year. The filing reports no interest-bearing debt — the 188.8M of total liabilities on the balance sheet are operating items (payables, leases, deferred taxes), not borrowings.
    What's free cash flow / what do these mean?

    Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.

    Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.

    Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.

    Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.

    THE KEY DEBATE

    What you actually need to decide

    Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

    🐂 The Bull Case
    For the stock to justify its premium, the company's drug pipeline must yield successful new product launches, expanding beyond its current primary revenue driver and sustaining its 20.1%/yr revenue growth.
    🐻 The Bear Case
    The low franchise/durability score of 2/5 implies that if competitive pressures intensify or pipeline drugs fail, the company's long-term profitability and revenue growth could be significantly challenged, making the current premium unsustainable.
    📌 Signposts to watch — update your view as these print
    • Next quarter's revenue growth rate
    • Updates on key clinical trial phases
    • Any new drug approvals or regulatory milestones
    MOMENTUM — WHAT'S GETTING BETTER & WORSE

    The trend, in plain numbers (FY2024 → FY2025, latest reported)

    Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

    ✅ Improving
    • Revenue grew +13% to $761.4M.
    ⚠ Worsening
    • Free cash flow fell to $57.3M.
    • Net income fell -29% to $99.7M.
    WHO

    Management & Leadership

    Joseph K. Belanoff, M.D., has served as CEO of Corcept Therapeutics since co-founding the company in 1998. He also serves as a director and is instrumental in the company's strategic direction and clinical development. The company focuses on developing and commercializing treatments for severe metabolic, oncologic, and psychiatric disorders.

    Joseph K. Belanoff
    Chief Executive Officer
    Gary Charles Robb
    Chief Medical Officer
    Sean Maduck
    Chief Commercial Officer
    WHAT

    What They Make

    Corcept Therapeutics develops and commercializes medications for severe endocrine, oncologic, and psychiatric disorders. Their primary product, Korlym, treats endogenous Cushing's syndrome, and they have a pipeline of other drug candidates.

    End Markets

    Endocrine disordersOncologyPsychiatric disorders

    Revenue Drivers

    Korlym sales
    Clinical trial advancements
    New drug approvals
    Market Cap: 13.5BBeta: 1.56
    WHY

    Why Is It Priced Like This?

    Why Customers Pay

    Addresses unmet medical needs for rare diseases
    Provides effective treatment for Cushing's syndrome
    Offers potential for new therapeutic options in pipeline
    No discounted-cash-flow value for this filer We aren't publishing a discounted-cash-flow value here: the model's output failed our plausibility checks, so showing it would imply more precision than we have.

    What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

    The market prices CORT at a significant premium of +366.7% to the model, likely due to its consistent financial health signals. The company has demonstrated revenue growth of 20.1%/yr and has been profitable for five consecutive years, with positive net income and operating cash flow in the latest period. The market may be assigning value to future drug pipeline catalysts, which is not in the model.

    HOW

    Business Model & Valuation

    How They Make Money

    Prescription drug sales (e.g., Korlym)
    Licensing agreements for drug candidates
    Research and development funding for pipeline

    The company funds itself through its positive operating cash flow, having been profitable for the past five years.

    Growth / Revenue DCF

    Extreme market premium (P/FCF 130x): market is pricing future growth far beyond current FCF. Using revenue/margin model.

    Show advanced inputs
    Revenue Growth20.1%

    What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

    WHEN

    Maturity & Competitive Position

    Growth-stage life sciences

    Moat Signals

    FDA-approved orphan drug status
    Proprietary drug formulations
    Clinical trial data and intellectual property

    Revenue has been growing at 20.1%/yr over four years, from $366M to $761M.

    WHERE

    Geography & Markets

    Corcept Therapeutics is a US-headquartered company, primarily operating within the United States market for its commercialized products. Geographic mix data is not available from current data sources.

    Geographic Risks

    Concentration risk on its primary commercialized drug, Korlym
    Regulatory approval risks for pipeline candidates
    SIGNALS

    Market Signals

    These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

    Model bearish, tape neutral
    RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
    Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
    Reference: 30–70 normal · >70 overbought · <30 oversold
    Full explanation →     (14)    84.2OverboughtBought up hard recently — stretched; pullbacks are common from here.
    MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
    Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
    Reference: Line above signal = bullish momentum · below = bearish
    Full explanation →    BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
    50-Day Average$48.03Price above (+134.8%)Price above its 50-day average = near-term uptrend.
    200-Day Average$59.48Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
    50 vs 200 CrossDeath50-day below 200-dayA "death cross" — the medium trend is below the long trend (often read as bearish).

    Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

    QUALITY

    Data Quality & Risk Flags (3 notes — click to expand/collapse)
    MEDIUM Operating CF declining
    Guardrail Notes (2)
    • Revenue/margin projection model used - trailing FCF may understate growth runway at current scale.
    • Price is far above the model output - market may be pricing optionality, narrative catalysts, or margin expansion beyond what trailing cash flows support.
    FINANCIALS

    Financial Statements (5-year tables — click to expand)

    From CORCEPT THERAPEUTICS INC's SEC filings (EDGAR).

    Income (5yr)

    YearRevenueNet IncomeEPS
    2025761.4M99.7M$0.82
    2024675.0M141.2M$1.23
    2023482.4M106.1M$0.94
    2022401.9M101.4M$0.87
    2021366.0M112.5M$0.89

    Cash Flow (5yr)

    YearOperating CFCapEx− SBC & adj.Free Cash Flow
    2025 142.0M 211,000 84.5M 57.3M
    2024 198.3M 2.2M 61.4M 134.8M
    2023 126.7M 139,000 48.9M 77.6M
    2022 120.3M 413,000 42.4M 77.5M
    2021 167.9M 469,000 42.9M 124.5M

    How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: 142.0M − 211,000 − 84.5M (SBC & adj.) = 57.3M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.

    Balance Sheet

    Total Assets836.7M
    Total Liabilities188.8M
    Equity647.8M
    YOU MIGHT ALSO LIKE

    Similar companies worth a look

    Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

    PG
    Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
    ⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
    ← Browse Stocks See sector peers →
    🔔 Follow $CORT — free insider alerts
    One email when an insider buys $CORT on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.